Jenny Thirlway

Jen leads Iksuda’s ADC programmes including the pre-clinical demonstration of Iksuda’s proprietary PermaLink conjugation chemistry, exemplification of novel toxin platforms and the evaluation of partnered antibodies/alternative scaffolds focussed on the development of a proof of concept stage ADC portfolio. Jen has significant experience in the development of biologics including antibody-based therapeutics and biosimilars (via the acquisition of Eden Biodesign Ltd, UK by Allergan PLC) and a post-doctoral background in biochemistry.